US4440778A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Anti-inflammatory analgesic cataplasm and process for producing the same
Assignee: Kowa Co Ltd
•
Filing: 1982-02-12
•
Granted: 1984-04-03
•
Expires: 2002-02-12
Abstract
Abstract An anti-inflammatory analgesic cataplasm is disclosed which comprises indomethacin as the active ingredient. Such cataplasm is produced by dissolving indomethacin in its non-ionic state, followed by the incorporation of water, a polyalcohol, a binder, a neutralizing agent and a vehicle, and homogenizing the resulting mixture into a paste.
Inventors
- 👤 Ichiro Matsui
- 👤 Tsutomu Tanaka
- 👤 Yukio Bando
- 👤 Kiyonobu Ohashi
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 16:01
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/40; A61K31/403; A61K31/404; A61K31/405; A61K9/00; A61K9/70; A61K9/7015; A61P; A61P29/00
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
137 words
An anti-inflammatory analgesic cataplasm comprising: indomethacin in the range of from 0.1 to 5.0 by weight; a polyalcohol selected from the group consisting of glycerin, polyethylene glycol, propylene glycol and sorbitol; a binder selected from the group consisting of gelatin, gum arabic, methyl cellulose, polyvinyl alcohol, hydroxyethyl cellulose, sodium polyacrylate, sodium carboxymethyl cellulose, sodium alginate, propylene glycol alginate, santan gum and a carboxyvinyl polymer; a vehicle selected from the group consisting of kaolin, bentonite, zinc oxide, titanium oxide and aluminum silicate; an aromatic alcohol selected from the group consisting of benzyl alcohol and phenethyl alcohol, or a non-ionic surfactant selected from the group consisting of polyoxyethylene sorbitan fatty acid ester and a sorbitan fatty acid ester or mixtures of said aromatic alcohol and said non-ionic surfactants; and water, said cataplasm having a pH of 5 to 7.
Claim 2
Dependent Claim
137 words
An anti-inflammatory analgesic cataplasm comprising: indomethacin in the range of from 0.1 to 5.0 by weight; a polyalcohol selected from the group consisting of glycerin, polyethylene glycol, propylene glycol and sorbitol; a binder selected from the group consisting of gelatin, gum arabic, methyl cellulose, polyvinyl alcohol, hydroxyethyl cellulose, sodium polyacrylate, sodium carboxymethyl cellulose, sodium alginate, propylene glycol alginate, santan gum and a carboxyvinyl polymer; a vehicle selected from the group consisting of kaolin, bentonite, zinc oxide, titanium oxide and aluminum silicate; an aromatic alcohol selected from the group consisting of benzyl alcohol and phenethyl alcohol, or a non-ionic surfactant selected from the group consisting of polyoxyethylene sorbitan fatty acid ester and a sorbitan fatty acid ester or mixtures of said aromatic alcohol and said non-ionic surfactants; and water, said cataplasm having a pH of 5 to 7.
Claim 3
Dependent Claim
73 words
The anti-inflammatory analgesic cataplasm according to claim 1, said polyalcohol being presented in the range of from 15 to 40% by weight, said binder in the range of from 10 to 20% by weight, said vehicle in the range of 10-20% by weight, and said aromatic alcohol, non-ionic surfactant or mixture of said aromatic alcohol and said non-ionic surfactant in the range of from 0.5 to 5.0% by weight, respectively, in the cataplasm.
Claim 4
Dependent Claim
51 words
A process for producing an anti-inflammatory analgesic cataplasm, comprising the steps of dissolving indomethacin in its non-ionic state, incorporating into the solution water, a polyalcohol, a binder, a neutralizing agent and a vehicle, and homogenizing the resulting mixture to form a paste, and if required, spreading said paste onto a substrate.
Claim 5
Dependent Claim
51 words
A process for producing an anti-inflammatory analgesic cataplasm, comprising the steps of dissolving indomethacin in its non-ionic state, incorporating into the solution water, a polyalcohol, a binder, a neutralizing agent and a vehicle, and homogenizing the resulting mixture to form a paste, and if required, spreading said paste onto a substrate.
Claim 6
Dependent Claim
28 words
The process as claimed in claim 3, said dissolving step being effected by dissolving said indomethacin in either one or both of an aromatic alcohol and a surfactant.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-04-03 | 1987-10-03 | 1988-04-03 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-04-03 | 1991-10-03 | 1992-04-03 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-04-03 | 1995-10-03 | 1996-04-03 | $7700.00 | Window Closed / Lapsed |